For instance, Han et al. suggested that HER2-positive early BC patients with a Val variant in the HER2Ile655Val SNP had a better survival when treated with TZ versus patients not receiving TZ, although the typed mutation itself would confer a more aggressive phenotype [17]. This evidence concerns the gene ERBB2 and breast cancer.